Compare Boeing Co (BA) vs Summit Therapeutics Inc (SMMT) Price & Performance

Boeing (BA) trades at $232.79, down 0.7% on the day, with a bullish technical signal supported by moving averages. The company reported revenue of $89.46B in 2025, swinging to a net income of $2.24B, and recent news highlights its strategic sale of non-core aviation technology units to Archer Aviation to sharpen focus on core aerospace and defense operations.

The outlook is positive with a consensus price target of $280.83, though high valuation ratios and volatile cash flows pose risks. Earnings momentum is mixed, with a recent Q2 2026 EPS miss, but analyst sentiment remains strongly bullish with 67% buy ratings.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.